Related Experiment Video

Updated: Jun 26, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

mTOR-understanding the clinical effects

A G Contreras1, O Dormond, M Edelbauer

  • 1Transplantation Research Center, Division of Nephrology, Department of Medicine, Children's Hospital Boston and the Department of Pediatrics, Harvard Medical School, Boston, Massachusetts 02115, USA.

Transplantation Proceedings
|December 23, 2008
PubMed

Insights

Mammalian target of rapamycin (mTOR) signaling regulates T cell and endothelial cell survival. Understanding mTOR pathways is crucial for optimizing mTOR inhibitors in solid organ transplantation and preventing rejection.

Area of Science:

  • Cell Biology
  • Immunology
  • Vascular Biology

Background:

  • The target of rapamycin (TOR) is a conserved serine/threonine kinase regulating cell growth and metabolism.
  • Mammalian target of rapamycin (mTOR) is the human homologue of yeast TOR, playing critical roles in cellular processes.
  • mTOR signaling is influenced by nutrients, growth factors, energy status, and cellular stress.

Purpose of the Study:

  • To review the role of mTOR-inducible signals in the protection and survival of effector and regulatory T cells.
  • To examine the function of mTOR in endothelial cell biology, including growth, survival, and proliferation.
  • To discuss the clinical relevance of mTOR in endothelial cells, particularly in the context of transplant rejection.

Main Methods:

  • Literature review focusing on mTOR signaling pathways.
  • Analysis of studies investigating mTOR's role in T cell and endothelial cell function.
  • Evaluation of clinical implications and therapeutic applications of mTOR inhibitors.

Main Results:

  • mTOR signaling is vital for the survival and function of both effector and regulatory T cells.
  • mTOR plays a significant role in vascular endothelial cell proliferation, survival, and overall health.
  • Dysregulation of mTOR in endothelial cells may contribute to the rejection process in solid organ transplantation.

Conclusions:

  • mTOR signaling is a key regulator of immune cell and vascular cell biology.
  • Targeting mTOR pathways offers therapeutic potential for managing transplant rejection.
  • Optimal use of mTOR inhibitors can improve outcomes following solid organ transplantation.

More Related Videos

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation09:37

A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation

Published on: March 15, 2018

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...